Lantern Pharma Inc. (LTRN) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Lantern Pharma Inc. on September 19, 2025. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol LTRN. The filing was signed on September 23, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Three primary matters were submitted to a vote of security holders:
- Director Elections: All six nominees were elected to the Board of Directors. The nominees are Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Lee T. Schalop, and David S. Silberstein. Each will serve until the 2026 Annual Meeting.
- Stock Option Repricing: Stockholders approved a one-time repricing of certain stock options under the 2018 Equity Incentive Plan. The vote was 1,458,333 For, 758,870 Against, and 29,603 Abstain.
- Auditor Ratification: Stockholders ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote was 7,365,922 For, 43,732 Against, and 26,426 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Investor Verification Checklist
- Verify the specific terms and financial impact of the approved stock option repricing in subsequent filings or the definitive proxy statement.
- Confirm the composition of the Board of Directors following the election of the six new directors.
- Review the upcoming 10-K or 10-Q for the fiscal year ending December 31, 2025, to obtain financial performance data not included in this 8-K.